Nowadays, with the recognition of EGFR and KRAS gene mutations, MET amplification and EML4-ALK rearrangements, new therapies directed against defined molecular targets profoundly impact on the non-small cell lung cancer (NSCLC) [1]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.